[Uterine sarcoma associated with tamoxifen use after breast cancer: Review of the pathogenesis].
Tamoxifen is widely used in the breast cancer treatment. Its side effects on the endometrium are well-known, but more and more worse prognosis uterine sarcoma are described. Based on recent literature review, the cause and effect chain between tamoxifen and uterine sarcoma is argued, which confirms that a risk exists as from 2 years of treatment, a cumulative dose of 15 g, and that malignant mixed mesodermal tumours appear to be the most frequent.
Homer
L
L
Service de gynécologie obstétrique et médecine de la reproduction, CHU de Brest, Brest 29200, France. lionelhomer@yahoo.fr
Muller
M
M
Dupré
P-F
PF
Lucas
B
B
Pradier
O
O
D001943:Breast Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D012307:Risk Factors; D012509:Sarcoma / Q000139:chemically induced* / Q000473:pathology; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000473:pathology
D013629:Tamoxifen